Award

National Institute of Allergy and Infectious Diseases RFA-AI-23-059

A Novel RAD51-BRCA2 Complex Stabilizing Drug: A Medical Countermeasure for Mitigating Accidental Radiation Exposure

Recipient

University of Arizona

Award Amount

$583,468.00

Ceiling

$583,468.00

Awarded

September 16, 2025

Identifier

RFA-AI-23-059

NIH awarded a grant to develop a drug stabilizing the RAD51-BRCA2 complex to mitigate radiation exposure effects, focusing on dosing optimization and efficacy evaluation, in collaboration with the University of Arizona.

Description

The project focuses on developing a small molecule drug to mitigate radiation-induced DNA damage, specifically targeting the BRCA2-RAD51 complex. The project aims to optimize dosing, elucidate mechanisms, and evaluate efficacy in mitigating gastrointestinal and cardiac toxicities. The award is administered by the NIH Office of the Director, with funding from the National Institute of Allergy and Infectious Diseases. The project involves collaboration with the University of Arizona.

View original record